Alzheimer’s Disease Screening Library

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting millions of patients and representing a major unmet medical need. Pathologically, AD is characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, leading to neuronal loss, synaptic dysfunction, and impaired neural communication [1]. These pathological changes primarily impact brain regions essential for cognition and memory, including the hippocampus and cerebral cortex.

Despite decades of intensive research, disease-modifying therapies for Alzheimer’s disease remain limited. Current approved treatments, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, provide only symptomatic relief and do not prevent or reverse disease progression [2]. As a result, there is an urgent need for novel therapeutic targets and innovative small-molecule modulators to advance Alzheimer’s drug discovery programs.

To address this challenge, our cheminformatics team has developed a comprehensive collection of over 18,000 carefully selected small molecules associated with key AD-related biological pathways. This Screening Library provides targeted chemical coverage of key pathological mechanisms associated with AD, including amyloid-beta and tau pathology, neuroinflammation, mitochondrial dysfunction, synaptic impairment, and defective proteostasis. By incorporating compounds with optimized physicochemical and drug-like properties, this Screening Library enables efficient hit identification and lead discovery against diverse Alzheimer’s disease-related targets in neurodegenerative research.

The compound selection can be customized based on your requirements, cherry picking is available.

Please, contact us at orders@lifechemicals.com for any additional information and price quotations.

Further exploring our related products will make your search even more rewarding:

• N-methyl-D-aspartate (NMDA) Receptor Screening Library
• Ion Channel Focused Library (Fingerprint Similarity)
• Glutamate Receptor Focused Library
• AKT Serine/threonine Kinase Targeted Library
• CNS Focused Screening Library

Compound Selection Strategy

To prepare this Screening Set, a ligand-based virtual screening approach was applied to our extensive HTS Compound Collection. 2D molecular fingerprints were employed to identify compounds structurally similar to known modulators of Alzheimer’s disease-associated targets.

A reference dataset was curated from the ChEMBL database and includes compounds with experimentally confirmed activity against AD-related targets. Compounds with a Tanimoto similarity coefficient ≥ 0.8 relative to reference molecules were selected, thereby ensuring a high chemical similarity to validated bioactive ligands. This data-driven selection strategy enriches the screening library with established and emerging chemotypes, while deliberately maintaining scaffold diversity, drug-like properties, and chemical novelty. Thus, a balanced and target-focused compound set suitable for both phenotypic and target-based screening campaigns was obtained.

Target Coverage

The Screening Library features over 18,000 small-molecule compounds designed to modulate a broad range of protein targets implicated in Alzheimer’s disease pathology, including :

Representative screening compounds from the Screening Library

F5098-1019

F3385-2596

F0580-0755

F3411-8570

F6677-1463

F3385-5221

F6753-0174

F0818-0038

F0669-0547

F1835-0009

F2608-2331

F1922-6718

F0580-0691

F0590-0229

F0477-0093

F0539-0108

F3222-1347

F6708-8429

Background: Alzheimer’s Disease Biology and Emerging Therapeutic Targets

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder with a complex etiology involving numerous interconnected molecular pathways. In addition to amyloid-beta and tau pathology, AD progression is driven by neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired protein clearance mechanisms. Genetic risk factors play a significant role, with mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes contributing to familial Alzheimer’s disease. At the same time, the apolipoprotein E (APOE) ε4 allele is a significant risk factor in sporadic AD cases [3]. Environmental influences, vascular health, and lifestyle factors further modulate disease susceptibility.

The repeated failure of late-stage clinical trials focused on amyloid-beta clearance, including programs based on anti-amyloid monoclonal antibodies, has prompted a strategic shift toward novel therapeutic targets and multi-target treatment approaches [4]. As a result, drug discovery efforts increasingly rely on diverse screening libraries designed to identify compounds that modulate multiple AD-relevant pathways, thereby enabling the discovery of disease-modifying therapies.

Recent advances in Alzheimer’s research have expanded the therapeutic landscape beyond amyloid and tau. Neuroinflammation has emerged as a key driver of disease progression, with microglial activation and the release of pro-inflammatory cytokines, such as IL-1β and TNF-α, contributing to neuronal injury [5]. Targeting microglial signaling pathways, including the TREM2 receptor, which regulates microglial phagocytosis and inflammatory responses, has demonstrated therapeutic potential in preclinical models [6]. Another emerging area of interest is the gut–brain axis, as accumulating evidence suggests that dysbiosis of the gut microbiota influences neuroinflammation and Alzheimer’s pathology [7]. Modulation of the microbiome or its metabolites, including short-chain fatty acids, represents a promising and novel therapeutic strategy.

Also, mitochondrial dysfunction and oxidative stress belong to the central components of AD pathogenesis. Impaired mitochondrial bioenergetics lead to excessive production of reactive oxygen species (ROS), which damage neurons and exacerbate tau pathology [8]. Drug discovery efforts are increasingly focused on compounds that regulate mitochondrial dynamics, such as fission and fusion, or those that enhance endogenous antioxidant defenses.

In parallel, synaptic dysfunction driven by amyloid-beta oligomers and tau aggregates disrupts neural plasticity and memory formation. Protein kinases involved in tau phosphorylation, including GSK-3β and CDK5, have emerged as attractive targets for restoring synaptic integrity and neuronal function [9]. Autophagy and proteostasis pathways are also of growing interest, as defective protein clearance contributes to the accumulation of amyloid-beta and tau. Enhancing lysosomal function or activating autophagy, for example, through modulation of the mTOR pathway, has shown promising results in preclinical studies [10].

The blood-brain barrier (BBB) remains a significant challenge in Alzheimer’s drug development, as many small molecules fail to achieve adequate brain exposure. Consequently, modern screening libraries increasingly prioritize compounds with favorable pharmacokinetic properties, including BBB permeability and CNS drug-likeness [11]. Meanwhile, precision medicine approaches that leverage biomarkers such as cerebrospinal fluid Aβ42/40 ratios, tau PET imaging, and genetic profiling are guiding patient stratification and target selection [12].

Together, these advances highlight the need for comprehensive, well-curated screening libraries that combine chemical diversity, biological relevance, and drug-like properties, enabling the identification of small molecules capable of modulating multiple Alzheimer’s disease-related pathways.

Figure 1. Diagram for the pathogenesis of AD, including the different hypotheses (picture adopted from Zhang, J., Zhang, Y., Wang, J. et al. [13]).

Figure 2. Mechanism behind Alzheimer's disease

References:

1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease. Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4.
2. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2024. Alzheimer's Dement (N Y). 2024 Apr 24;10(2):e12465. Dutch. Doi: 10.1002/trc2.12465. 
3. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015 Jan 1;77(1):43-51. doi: 10.1016/j.biopsych.2014.05.006.
4. Long JM, Holtzman DM. Alzheimer's Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019 Oct 3;179(2):312-339. doi: 10.1016/j.cell.2019.09.001. 
5. Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D, Brosseron F, Teunissen C, Zetterberg H, Jacobs AH, Edison P, Ramirez A, Cruchaga C, Lambert JC, Laza AR, Sanchez-Mut JV, Fischer A, Castro-Gomez S, Stein TD, Kleineidam L, Wagner M, Neher JJ, Cunningham C, Singhrao SK, Prinz M, Glass CK, Schlachetzki JCM, Butovsky O, Kleemann K, De Jaeger PL, Scheiblich H, Brown GC, Landreth G, Moutinho M, Grutzendler J, Gomez-Nicola D, McManus RM, Andreasson K, Ising C, Karabag D, Baker DJ, Liddelow SA, Verkhratsky A, Tansey M, Monsonego A, Aigner L, Dorothée G, Nave KA, Simons M, Constantin G, Rosenzweig N, Pascual A, Petzold GC, Kipnis J, Venegas C, Colonna M, Walter J, Tenner AJ, O'Banion MK, Steinert JR, Feinstein DL, Sastre M, Bhaskar K, Hong S, Schafer DP, Golde T, Ransohoff RM, Morgan D, Breitner J, Mancuso R, Riechers SP. Neuroinflammation in Alzheimer's disease. Nat Rev Immunol. 2025 May;25(5):321-352. doi: 10.1038/s41577-024-01104-7. 
6. Ulrich JD, Holtzman DM. TREM2 Function in Alzheimer's Disease and Neurodegeneration. ACS Chem Neurosci. 2016 Apr 20;7(4):420-7. doi: 10.1021/acschemneuro.5b00313.
7. Murray ER, Kemp M, Nguyen TT. The Microbiota-Gut-Brain Axis in Alzheimer's Disease: A Review of Taxonomic Alterations and Potential Avenues for Interventions. Arch Clin Neuropsychol. 2022 Feb 22;37(3):595-607. doi: 10.1093/arclin/acac008.
8. Wu Y, Chen M, Jiang J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion. 2019 Nov;49:35-45. doi: 10.1016/j.mito.2019.07.003. 
9. Karati D, Meur S, Roy S, Mukherjee S, Debnath B, Jha SK, Sarkar BK, Naskar S, Ghosh P. Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer's disease. Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):2319-2342. doi: 10.1007/s00210-024-03500-1. 
10. Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, Füllgrabe J, Jackson A, Jimenez Sanchez M, Karabiyik C, Licitra F, Lopez Ramirez A, Pavel M, Puri C, Renna M, Ricketts T, Schlotawa L, Vicinanza M, Won H, Zhu Y, Skidmore J, Rubinsztein DC. Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. Neuron. 2017 Mar 8;93(5):1015-1034. doi: 10.1016/j.neuron.2017.01.022. 
11. Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016 Apr;15(4):275-92. doi: 10.1038/nrd.2015.21.
12. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, van der Flier WM, Mielke MM, Del Campo M. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6.
13. Zhang, J., Zhang, Y., Wang, J. et al. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Sig Transduct Target Ther9, 211 (2024). https://doi.org/10.1038/s41392-024-01911-3